Literature DB >> 23583840

Comparative study of Pluronic(®) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats.

Dan Chen1, Dengning Xia, Xiuying Li, Quanlei Zhu, Hongzhen Yu, Chunliu Zhu, Yong Gan.   

Abstract

Liposomes modified using cationic and hydrophilic nonionic polymers are 2 popular carriers for improving oral drug absorption. Cationic polymer-modified liposomes can adhere to the intestinal wall mucus (mucoadhesive type), while liposomes modified using hydrophilic nonionic polymers can penetrate across the mucus barrier (mucus-penetrating type). Chitosan-modified liposomes (CS-Lip, mucoadhesive type) and Pluronic(®) F127-modified liposomes (PF127-Lip, mucus-penetrating type) were engineered to investigate the differences between these mucoadhesive and mucus-penetrating systems in oral absorption of a poorly soluble drug, cyclosporine A (CyA). Stability of CS-Lip and PF127-Lip was studied in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). The intestinal mucus adhesion or penetration of liposomes was studied by confocal laser scanning microcopy and fluorophotometry using coumarin 6 as the fluorescent probe. The oral absorption of CyA-loaded liposomes was also studied in Sprague-Dawley rats. In vitro and in vivo studies revealed that CS-Lip tended to aggregate in SIF, to be trapped by mucus, to remain mainly in the upper portion of the intestinal tract, and to show limited penetration ability. In contrast, PF127-Lip were more stable in the SIF and SGF, were found throughout the intestinal tract, and were able to penetrate the mucus layers to reach the epithelial surface. Pharmacokinetic analysis in rats showed that the Cmax and AUC0-t of PF127-Lip were 1.73- and 1.84-fold higher than those of CS-Lip, respectively (P<0.05). In conclusion, the stability and mucus-penetrating ability of PF127-Lip in the gastrointestinal tract rendered it more suitable than the mucoadhesive CS-Lip for oral delivery CyA.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23583840     DOI: 10.1016/j.ijpharm.2013.04.002

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  18 in total

1.  Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.

Authors:  Javier O Morales; Kristin R Fathe; Ashlee Brunaugh; Silvia Ferrati; Song Li; Miguel Montenegro-Nicolini; Zeynab Mousavikhamene; Jason T McConville; Mark R Prausnitz; Hugh D C Smyth
Journal:  AAPS J       Date:  2017-02-13       Impact factor: 4.009

2.  Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse.

Authors:  Katharina Maisel; Laura Ensign; Mihika Reddy; Richard Cone; Justin Hanes
Journal:  J Control Release       Date:  2014-11-04       Impact factor: 9.776

3.  Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.

Authors:  Fengqiao Li; Hao Mei; Xiaodong Xie; Huijuan Zhang; Jian Liu; Tingting Lv; Huifang Nie; Yu Gao; Lee Jia
Journal:  AAPS J       Date:  2017-02-23       Impact factor: 4.009

4.  PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination.

Authors:  Hardeep S Oberoi; Yvonne M Yorgensen; Audrey Morasse; Jay T Evans; David J Burkhart
Journal:  J Control Release       Date:  2015-11-06       Impact factor: 9.776

5.  Precisely Fabricated Sulpiride-Loaded Nanolipospheres with Ameliorated Oral Bioavailability and Antidepressant Activity.

Authors:  Salma M Mohyeldin; Wael M Samy; Doaa Ragab; Doaa A Abdelmonsif; Rania G Aly; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2021-03-09

6.  PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency.

Authors:  Fei Yu; Mingtao Ao; Xiao Zheng; Nini Li; Junjie Xia; Yang Li; Donghui Li; Zhenqing Hou; Zhongquan Qi; Xiao Dong Chen
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Preparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability.

Authors:  Chunying Zeng; Fanglin Yu; Yang Yang; Xiaohui Cheng; Yan Liu; Hui Zhang; Shiqing Zhao; Zhenbo Yang; Mingyuan Li; Zhiping Li; Xingguo Mei
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

8.  Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice.

Authors:  Shreyasi Chakraborty; Nabanita Kar; Leena Kumari; Asit De; Tanmoy Bera
Journal:  Int J Nanomedicine       Date:  2017-07-07

9.  Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice.

Authors:  Yi Chen; Zhaohui Jiang; Jinzhuan Xu; Jiyuan Zhang; Runbin Sun; Jia Zhou; Yuan Lu; Zipeng Gong; Jing Huang; Xiangchun Shen; Qianming Du; Jianqing Peng
Journal:  J Nanobiotechnology       Date:  2021-08-04       Impact factor: 10.435

10.  Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.

Authors:  Melissa Guada; Victor Sebastián; Silvia Irusta; Esperanza Feijoó; María del Carmen Dios-Viéitez; María José Blanco-Prieto
Journal:  Int J Nanomedicine       Date:  2015-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.